Shoulder Innovations, Inc. (NYSE:SI) Stock Has Consensus Price Target of $25.75 According to Brokerages

Key Points

• Shoulder Innovations has a “Moderate Buy” consensus rating from six brokerages, with five buys and one sell. The average 12-month price target is $25.75, with recent targets ranging from $25 to $28.
• The company reported quarterly revenue of $17.18 million and an adjusted loss of $0.49 per share, missing the $0.46 loss expected by analysts. Analysts project a full-year loss of approximately $1.90 per share.
• Insiders sold 227,243 shares worth about $5.1 million over the past 90 days, while corporate insiders retain a 29% ownership stake. Several institutional investors, including Roubaix Capital and Royal Bank of Canada, increased their positions.

Shoulder Innovations, Inc. (NYSE:SI - Get Free Report) has earned an average rating of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $25.75.

A number of equities analysts have recently commented on SI shares. UBS Group raised their price objective on Shoulder Innovations from $27.00 to $28.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Piper Sandler reaffirmed an "overweight" rating and issued a $25.00 price objective (up from $19.00) on shares of Shoulder Innovations in a research note on Friday, August 7th. Weiss Ratings upgraded Shoulder Innovations from a "sell (d-)" rating to a "sell (d)" rating in a report on Monday, August 3rd. Finally, BTIG Research increased their target price on shares of Shoulder Innovations from $26.00 to $27.00 and gave the stock a "buy" rating in a research report on Monday, October 12th.

Shoulder Innovations Stock Down 0.5%

Shares of SI opened at $19.66 on Friday. Shoulder Innovations has a fifty-two week low of $10.92 and a fifty-two week high of $24.59. The company's fifty day moving average is $19.36 and its two-hundred day moving average is $18.20. The firm has a market cap of $409.30 million, a PE ratio of -10.24 and a beta of -1.58. The company has a quick ratio of 8.92, a current ratio of 10.71 and a debt-to-equity ratio of 0.12.

Shoulder Innovations (NYSE:SI - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.03). Shoulder Innovations had a negative return on equity of 23.61% and a negative net margin of 58.33%. The firm had revenue of $17.18 million for the quarter. Analysts forecast that Shoulder Innovations will post -1.90 earnings per share for the current year.

Insider Buying and Selling at Shoulder Innovations

In other news, major shareholder Healthcare Holding B.V. Gilde sold 99,812 shares of the stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $22.77, for a total value of $2,272,719.24. Following the completion of the sale, the insider owned 2,221,640 shares of the company's stock, valued at $50,586,742.80. This represents a 4.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Matthew Fraser Ahearn sold 14,186 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $20.99, for a total transaction of $297,764.14. Following the completion of the sale, the chief operating officer directly owned 244,176 shares of the company's stock, valued at $5,125,254.24. The trade was a 5.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 227,243 shares of company stock valued at $5,092,575 over the last ninety days. Corporate insiders own 29.00% of the company's stock.

Institutional Trading of Shoulder Innovations

A number of institutional investors have recently added to or reduced their stakes in the business. Roubaix Capital LLC grew its holdings in Shoulder Innovations by 61.9% during the 1st quarter. Roubaix Capital LLC now owns 257,121 shares of the company's stock valued at $3,736,000 after purchasing an additional 98,305 shares in the last quarter. Royal Bank of Canada lifted its holdings in Shoulder Innovations by 7,046.3% in the 1st quarter. Royal Bank of Canada now owns 53,883 shares of the company's stock worth $783,000 after buying an additional 53,129 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Shoulder Innovations in the 2nd quarter worth $896,000. KCM Capital Inc acquired a new position in Shoulder Innovations in the 1st quarter worth $509,000. Finally, Bank of New York Mellon Corp purchased a new position in Shoulder Innovations in the 1st quarter valued at about $252,000.

About Shoulder Innovations

Shoulder Innovations, Inc is a medical device company focused on developing and commercializing products for shoulder arthroplasty, or shoulder replacement surgery. The company aims to address challenges associated with conventional shoulder-replacement procedures through implant designs intended to support surgical efficiency, fixation, and patient outcomes.

Its product portfolio includes shoulder replacement systems and related components, including glenoid implants and technologies designed for anatomic and reverse shoulder arthroplasty procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.